Best of foregut: esophagus, stomach, and duodenum

Therapies for bleeding gastric varices: is the fog starting to clear?

Pharynx and esophagus: Esophageal benign diseases.

Gastrointestinal bleeding

Tu1328 Endoscopic Submucosal Dissection for Barrett's Esophagus: Efficacy and Safety Results in a Large Tertiary Center Series of Patients

Endoscopic Therapy for Barrett's Esophagus

Adverse events associated with EGD and EGD-related techniques

Getting into a TIF(F) Over Fundoplication

Intravenous proton pump inhibitors: requiem for endoscopic therapy?

A critical look at endoscopic eradication therapy for Barrett's esophagus: are we putting the cart before the horse?

Mo1239 COMPARATIVE OUTCOMES OF CAP ASSISTED ENDOSCOPIC RESECTION AND ENDOSCOPIC SUBMUCOSAL DISSECTION IN PATIENTS WITH DYSPLASTIC BARRETT'S ESOPHAGUS AND INTRAMUCOSAL ADENOCARCINOMA

Endoscopic eradication therapy (EET) combining endoscopic resection (ER) with endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) followed by ablation is the standard of care for the treatment of dysplastic Barrett's esophagus (BE). We have previously shown comparable rates of complete remission of intestinal metaplasia (CRIM) with both approaches. However, data comparing recurrence after CRIM are lacking. We compared rates of recurrence after CRIM with both techniques in a multicenter cohort. Patients undergoing EET achieving CRIM at 3 academic institutions were included. Demographic and clinical data were abstracted. Outcomes included rates and predictors of any BE and dysplastic BE recurrence in the 2 groups. Cox-proportional hazards models and inverse probability treatment weighting (IPTW) analysis were used for analysis. A total of 621 patients (514 EMR and 107 ESD) achieving CRIM were included in the recurrence analysis. The incidence of any BE (15.7, 5.7 per 100 patient-years) and dysplastic BE recurrence (7.3, 5.3 per 100 patient-years) were comparable in the EMR and ESD groups, respectively. On multivariable analyses, the chances of BE recurrence were not influenced by ER technique (hazard ratio 0.87; 95% confidence interval 0.51-1.49; P = 0.62), which was also confirmed by IPTW analysis (ESD vs EMR: hazard ratio 0.98; 95% confidence interval 0.56-1.73; P = 0.94). BE length, lesion size, and history of cigarette smoking were independent predictors of BE recurrence. Patients with BE dysplasia/neoplasia achieving CRIM, initially treated with EMR/ablation, had comparable recurrence rates to ESD/ablation. Randomized trials are needed to confirm these outcomes between the 2 ER techniques.

Much ado about very little (lamina propria)?

Core curriculum for endoscopic submucosal dissection (ESD)

Comprehensive analysis of efficacy and safety of peroral endoscopic myotomy performed by a gastroenterologist in the endoscopy unit: a single-center experience

Mo1293 FACTORS ASSOCIATED WITH LACK OF COMPLETE REMISSION OF INTESTINAL METAPLASIA IN PATIENTS WITH BARRETT’S ESOPHAGUS ASSOCIATED HIGH GRADE DYSPLASIA AND INTRAMUCOSAL CANCER